Continuous Renal Replacement Therapy Market Research Report Information by Product (Dialysates and Replacement Fluids, Disposables [Hemofilters, Bloodline Sets and Tubes, and Others] and, CRRT System), By Modality (Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Diafiltration (CVVHDF), Continuous Venovenous Hemodialysis (CVVHD), and Slow Continuous Ultrafiltration (SCUF)), By Age Group (Geriatric, Adults, and Pediatrics & Neonates), and By End User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics) and by Reg

Global Continuous Renal Replacement Therapy Market Overview

Continuous Renal Replacement Therapy Market Size was valued at USD 1.48 Billion in 2023. The Global Continuous Renal Replacement Therapy industry is projected to grow from USD 1.59 Billion in 2024 to USD 2.82 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.3% during the forecast period (2024 - 2032).

Continuous renal replacement therapy (CRRT) is used in critically ill patients, especially those who are hemodynamically unstable. There are several advantages of CRRT, including continuous control of fluid status, control of acid-base status, the ability to provide protein-rich nutrition while achieving uremic control, and hemodynamic stability. There are several factors affecting the global CRRT market, including the increasing prevalence of chronic kidney diseases and the rising geriatric population. However, the rising number of complications associated with CRRT is hindering the growth of the market. Moreover, the rise in demand in developing regions is projected to show lucrative growth opportunities during the forecast period.

COVID-19 Analysis

The supply chain in the global market for continuous renal replacement therapy is the key to fulfilling customer demands. As a result of the pandemic, a number of countries-imposed import and export restrictions. This has also affected the healthcare industry, as many countries are dependent on other countries for raw material supply and technology. Additionally, both central and state agencies have struggled to take palliative and preventative measures. Moreover, COVID-19 affects multiple organs in the body. It has worsened the conditions of kidney failure in patients. In addition, CRRT demand was high during the COVID-19 pandemic. Patients with acute kidney failure who also had a COVID-19 infection were at high risk of death. Moreover, during the pandemic, doctors recommended CRRT instead of conventional therapy to reduce the chances of death. Furthermore, the impact on the market was not severe as the demand for CRRT was continuous. However, the delay in performing the CRRT and the fact that hospitals were unable to provide CRRT due to the system's low availability further harmed the market. Moreover, by the end of 2020 and 2021, the supply chain seemed to recover, and the market slowly observed a return to pre-COVID-19 levels as patients started to follow their routines without delaying their treatment.

Continuous Renal Replacement Therapy Market Trends

Market Drivers

• Increasing prevalence of chronic kidney diseases
  
  
  
  • The increase in the prevalence of kidney diseases may lead to acute kidney injury (AKI), which further increases the demand for CRRT. There are several diseases that increase the prevalence of AKI, including diabetes, high blood pressure, polycystic kidney disease, recurrent kidney infections, and glomerulonephritis. Furthermore, in November 2021, as per the International Society of Nephrology (ISN), 13.3 million people experienced AKI every year. As a result, the rising prevalence of kidney diseases and AKI further supports market growth.
  
  
  
  


• Rising geriatric population

Market Restraints

• Growing number of complications associated with CRRT
  
  
  
  • There are several technical complications related to CRRT that doctors and staff face with patients on a daily basis. The complications can be activation of the coagulation system, fluid balance errors, air embolism, heat loss and hypothermia, immune system activation, and vascular access dysfunction. Furthermore, there is a high need for CRRT operations to analyze the complications in order to mitigate the risk. Moreover, according to several studies, there are high chances of catheterization-related insertion complications, electrolyte disturbances, hypotension, and hemorrhage in children. Hence, the complications are increasing in all age groups of patients, further retarding the market's growth.
  
  
  
  

Market Opportunities

• Rise in demand in developing regions
  
  
  
  • The increasing geriatric population and the large number of people in developing regions further create lucrative growth opportunities. In July 2022, according to the Pew Research Center, China and India have the world's largest populations. Moreover, the older population is more susceptible to renal diseases. This is because comorbid conditions including arterial hypertension, diabetes mellitus, and chronic heart failure may lead to renal damage. In October 2022, as per the World Health Organization, 80% of the older population will be living in low- and middle-income countries (LMICs) by 2050. In addition, the population's rapid urbanization and unhealthy lifestyle in countries in developing regions, including Afghanistan, Bangladesh, Bhutan, Somalia, Syria, and Yemen, create lucrative market growth opportunities.
  
  
  
  

Value Chain Analysis

The global continuous renal replacement therapy market is projected to exhibit significant growth over the forecast period, which can be attributed to factors like the rising geriatric population and increasing prevalence of kidney diseases. The value chain analysis for the market comprises five major components, which start with research and product development, followed by the manufacturing of the products, distribution, and sales, and end with post-marketing surveillance.

Continuous Renal Replacement Therapy Market Segment Insights

Continuous renal replacement therapy Product Insights

• Dialysates and Replacement Fluids

Dialysate and replacement fluids are used to achieve fluid balance in hemofiltration and primarily convective therapy for the transfer of solute and water across a semipermeable membrane. These are sterilized and warmed to body temperature. Replacement fluid is used in hemofiltration to dilute the post-filter blood, buffer the blood as it returns to the patient, and restore volume. Moreover, as per research, companies are experiencing huge demand for dialysate and replacement fluids across the world, which further supports the segment's growth.

Disposables Insights

Disposables include hemofilters, bloodline sets & tubes, and others. The hemofilter is used to pull down the large volume of water. The convection in the hemofilter enhances the removal of small and medium-sized molecules. Moreover, bloodline sets, and tubes are intended to improve the procedure's safety and efficiency.  Further, these are used to administer replacement & dialysate fluids and anticoagulants. In addition, these are intended to transfer blood from patients’ vascular access systems to the hemodialyzer.

CRRT System Inisghts

Continuous renal replacement therapy (CRRT) system is a type of blood purification machine. This device controls the rate of blood flow and includes software to safely monitor therapy delivery. The system performs therapies including continuous venovenous hemofiltration (CVVH), continuous venovenous diafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF).

Continuous renal replacement therapy Modality Insights

• Continuous Venovenous Hemofiltration (CVVH)

Continuous venous hemofiltration (CVVH) is a short-term treatment for patients suffering from acute renal failure. This therapy is suitable for patients who are unable to tolerate hemodialysis. This therapy uses convective clearance in order to remove toxins and solutes from the patient's circulation. The advantages include hemodynamic stability, optimal clearance of uremic toxins, and liberal fluid management.

• Continuous Venovenous Diafiltration (CVVHDF)

The continuous venovenous hemodiafiltration (CVVHDF) method uses replacement fluid and dialysate. It combines both diffusion and convection for solute removal. Dialysate and replacement fluids can be used simultaneously in various combinations at various rates in this method. It reduces the mortality rate and hospital length of stay. This method is also used for cancer patients suffering from AKI.

• Continuous Venovenous Hemodialysis (CVVHD)

Continuous venous hemodialysis (CVVHD) is used for critically ill patients. CVVHD is used to remove both solute and fluid. As per several research studies, CVVHD is more frequently used across the globe, especially in developed regions. There is no replacement fluid used in this method. Moreover, this method is also effective for removing small to medium-sized molecules.

• Slow Continuous Ultrafiltration (SCUF)

Slow continuous ultrafiltration (SCUF) is used for the treatment of oliguric acute renal dysfunction. Furthermore, the hemodynamic parameters remain stable while significant amounts of fluid are removed using this method. This is suited for patients with fluid overload and renal insufficiency.

Continuous renal replacement therapy Age Group Insights

• Geriatric

The incidence of acute renal failure increases with growing age. This is due to physiological changes, multiple comorbidities, and lower renal reserves. Furthermore, the geriatric population is more likely to have acute renal failure due to increased medication use and the need for multiple procedures. In addition, AKI is more common in elderly patients. However, continuous renal replacement therapy is used less frequently in the geriatric population than in the younger generation.

• Adults

Continuous renal replacement therapy is most commonly used in adults. This is used impulsively in adults and provides frequent relief to critically ill patients. Some common diseases that occur in adults are hypovolemia, glomerulonephritis, and sepsis. These diseases may lead to acute kidney failure in adults.

• Pediatrics & Neonates

Continuous renal replacement therapy is used to maintain hemodynamics in critically ill pediatric and neonatal patients. The advantage of the CRRT in pediatric and neonatal age groups is that the CRRT promote both solute and fluid clearance in a slow and continuous manner. Acute kidney failure is most common in neonates at higher risk. The development of AKI in pediatrics and neonates occurs often owing to prematurity, respiratory and vascular disorders, congenital uropathies, heart failure, and the use of nephrotoxic drugs.

Continuous renal replacement therapy End User Insights

• Hospitals

Continuous renal replacement therapy is widely used in hospitals. Hospitals that provide dialysis improve the overall health and quality of life of patients with acute renal failure. Moreover, in order to perform CRRT, hospitals require an interprofessional healthcare team. Furthermore, hospitals are working with specialists in fields such as neurology, nephrology, and critical care, to develop strategies for when to remove solutes & fluids and administer anticoagulation, further supporting the segmental growth. In hospitals, CRRT is performed in the intensive care unit (ICU), coronary care unit (CCU), and emergency medical center.

• Ambulatory Surgical Centers

The most common complication that can happen to patients undergoing surgery at ambulatory surgical centers is AKI.  AKI is a short-term complication that occurs after surgery or during major surgeries. If left untreated, AKI can result in long-term negative outcomes. AKI is commonly observed following cardiac surgery in which CRRT is required. However, there have been fewer chances of AKI in patients who underwent gastrointestinal surgery.

• Specialty Clinics Insights

Specialized clinics include cardiology, gastroenterology, gynecology, obstetrics, and neurology specialties. These clinics have trained nurses and technicians to perform CRRT on patients with acute renal failure. Cardiology clinics are required to keep CRRT on hand in case patients require it unexpectedly. The gastroenterology clinics also require the CRRT system if the patient is suffering from acute liver failure.

Continuous renal replacement therapy Regional Insights

The global continuous renal replacement therapy market based on the region has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

North America

The increasing incidences of comorbidities diseases, adoption of sedentary lifestyle & physical inactivity are expected to propel the market growth in the region.

The North America region is expected to hold the highest market share during the forecast period. This is due to several factors, including the rising prevalence of comorbid diseases such as diabetes and obesity, and adoption of sedentary lifestyle is prevalent in the region. In November 2022, as per the Census Bureau, more than 34 million people are living with diabetes in America. Poorly controlled diabetes can damage the blood vessels of kidney further may lead to acute kidney failure. Moreover, the companies launch new products to meet the needs of patients and physicians, such as critically ill patients. For instance, in December 2020, Medtronic plc (Ireland) launched the Carpediem Cardio-Renal Pediatric Dialysis Emergency Machine for the pediatric and neonatal population in Cincinnati Children's Hospital Medical Center (US). Therefore, the increasing prevalence of comorbid diseases and growth strategies support market growth in the region.

Competitive Landscape

Market players are improving business through planning and adopting new strategies to increase their market presence. Moreover, they are adopting several strategic initiatives with regard to continuous renal replacement therapy, such as new product launches, contractual agreements, mergers, and acquisitions, increasing investments, and partnerships among players are aiding to expand the continuous renal replacement therapy field across the globe.

Baxter International, Inc. (US) is one of the key market players, founded in 1931. It is a global healthcare company that offers medical devices and surgical instruments in the healthcare market. It operates through six major business segments: renal care, medication delivery, pharmaceuticals, advanced surgery, clinical nutrition, and acute therapies. In October 2018, Baxter International Inc. launched the PrisMax system and its TherMax blood warmer. It is designed to deliver therapy simpler and more efficient.

List of companies covered in this report:

• Baxter International, Inc. (US)


• Medtronic plc (Ireland)


• Fresenius Medical Care (US)


• Braun Medical Inc. (US)


• Nikkiso Co. (Japan)


• Asahi Kasei Corporation (Japan)


• Toray Medical Co. Ltd (Japan)


• Infomed SA (Switzerland)


• SWS Heamodialysis Care Co. Ltd (China)


• Medites Pharma spol. s.r.o. (Czech Republic)


• Others

Recent Developments

• In August 2022, Fresenius Medical Care (US) launched the Speedwap. This system is designed to reduce therapy downtime and lower treatment costs.


• In June 2022, Nikkiso Co. (US) partnered with Cytosorbent Corporation (US) in order to distribute Nikkiso's PureADJUST hemoperfusion blood pump.


• In June 2022, B. Braun Medical Inc. (US) launched the Xevonta in the US market, and this is a next-generation dialyser. It is designed to improve clearance performance by removing more toxins from a patient's blood.

Report Overview

The study covers the existing short-term and long-term market effects. It helps decision-makers to draw up short-term and long-term business plans by region. The report covers major regions in North America, Europe, Asia-Pacific, and the rest of the world. The report analyses market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.

Study Objectives

• To provide a detailed analysis of the market structure and forecast for the various segments of the global continuous renal replacement therapy market over the next eight years.


• To provide insights about factors affecting the market's growth.


• To analyzes the global continuous renal replacement therapy market based on numerous factors such as price analysis, supply chain analysis, Porter's five force analysis, etc.


• To provide historical and forecast revenues of the market segments and sub-segments concerning four main geographies and their countries: North America, Europe, Asia-Pacific, and the Rest of the World.


• To provide a country-level market analysis for the current market size and prospects.


• To provide a country-level analysis of the market for segments by product, modality, age group, and end-user.


• To provide strategic profiling of key players in the market, comprehensively analyze their core competencies, and draw a competitive market landscape.


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers & acquisitions, new product developments, and R&D in the global continuous renal replacement therapy market.

Continuous Renal Replacement Therapy Market Segmentation:

Continuous Renal Replacement Therapy Market, Product Outlook

• Dialysates and Replacement Fluids


• Disposables
  
  
  
  • Hemofilters
  
  
  • Bloodline Sets and Tubes
  
  
  • Others
  
  
  
  


• CRRT System

 Continuous Renal Replacement Therapy Market, Modality Outlook

• Continuous Venovenous Hemofiltration (CVVH)


• Continuous Venovenous Diafiltration (CVVHDF)


• Continuous Venovenous Hemodialysis (CVVHD)


• Slow Continuous Ultrafiltration (SCUF)

Continuous Renal Replacement Therapy Market, Age group Outlook

• Geriatric


• Adults


• Pediatrics & Neonates

Continuous Renal Replacement Therapy Market, End User Outlook

• Hospitals


• Ambulatory Surgical Centers


• Specialty Clinics

Continuous Renal Replacement Therapy Market, Region Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Intended Audience:

• Continuous Renal Replacement Therapy Manufacturers and Suppliers


• Research and Development (R&D) Companies


• Healthcare Providers


• Government & Independent Research Laboratories


• Government and Independent Regulatory Authorities


• Market Research and Consulting Service Providers


• Academic Institutes and Universities